ECSP034682A - Antagonistas de receptores de aminoacidos excitatorios - Google Patents
Antagonistas de receptores de aminoacidos excitatoriosInfo
- Publication number
- ECSP034682A ECSP034682A EC2003004682A ECSP034682A ECSP034682A EC SP034682 A ECSP034682 A EC SP034682A EC 2003004682 A EC2003004682 A EC 2003004682A EC SP034682 A ECSP034682 A EC SP034682A EC SP034682 A ECSP034682 A EC SP034682A
- Authority
- EC
- Ecuador
- Prior art keywords
- ancigonists
- receivers
- amino acids
- excitatory amino
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una sal farmacéutica mente aceptable de un compuesto de fórmula: (gráfico) o un pro fármaco del mismo en la que la sal farmaceúticamente aceptable se selecciona del grupo constituido por la sal del ácido D-( -)-mandélico o la sal del ácido 1, 5-naftalenodisulfónico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26001401P | 2001-01-05 | 2001-01-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP034682A true ECSP034682A (es) | 2003-08-29 |
Family
ID=22987455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2003004682A ECSP034682A (es) | 2001-01-05 | 2003-07-03 | Antagonistas de receptores de aminoacidos excitatorios |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1351955A1 (es) |
JP (1) | JP2004520335A (es) |
KR (1) | KR20030066797A (es) |
CN (1) | CN1484642A (es) |
AR (1) | AR035679A1 (es) |
BR (1) | BR0116672A (es) |
CA (1) | CA2431545A1 (es) |
CZ (1) | CZ20031856A3 (es) |
DZ (1) | DZ3460A1 (es) |
EA (1) | EA200300770A1 (es) |
EC (1) | ECSP034682A (es) |
HR (1) | HRP20030544A2 (es) |
HU (1) | HUP0302528A2 (es) |
IL (1) | IL156138A0 (es) |
MX (1) | MXPA03005981A (es) |
NO (1) | NO20032973D0 (es) |
NZ (1) | NZ525821A (es) |
PE (1) | PE20020792A1 (es) |
PL (1) | PL361934A1 (es) |
SK (1) | SK8242003A3 (es) |
TW (1) | TW591023B (es) |
WO (1) | WO2002053561A1 (es) |
ZA (1) | ZA200304311B (es) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5284957A (en) * | 1992-09-03 | 1994-02-08 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
JP2002505254A (ja) * | 1998-02-06 | 2002-02-19 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | パロキセチン塩 |
GB9908175D0 (en) * | 1999-04-09 | 1999-06-02 | Lilly Co Eli | Method of treating neurological disorders |
TR200200066T2 (tr) * | 1999-07-06 | 2002-04-22 | Eli Lilly And Company | Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri |
-
2001
- 2001-12-20 KR KR10-2003-7008977A patent/KR20030066797A/ko not_active Application Discontinuation
- 2001-12-20 NZ NZ525821A patent/NZ525821A/en unknown
- 2001-12-20 HU HU0302528A patent/HUP0302528A2/hu unknown
- 2001-12-20 WO PCT/US2001/044715 patent/WO2002053561A1/en not_active Application Discontinuation
- 2001-12-20 EA EA200300770A patent/EA200300770A1/ru unknown
- 2001-12-20 CZ CZ20031856A patent/CZ20031856A3/cs unknown
- 2001-12-20 IL IL15613801A patent/IL156138A0/xx unknown
- 2001-12-20 EP EP01995980A patent/EP1351955A1/en not_active Withdrawn
- 2001-12-20 PL PL01361934A patent/PL361934A1/xx not_active Application Discontinuation
- 2001-12-20 BR BR0116672-7A patent/BR0116672A/pt not_active IP Right Cessation
- 2001-12-20 CA CA002431545A patent/CA2431545A1/en not_active Abandoned
- 2001-12-20 JP JP2002554680A patent/JP2004520335A/ja active Pending
- 2001-12-20 DZ DZ013460A patent/DZ3460A1/fr active
- 2001-12-20 MX MXPA03005981A patent/MXPA03005981A/es unknown
- 2001-12-20 SK SK824-2003A patent/SK8242003A3/sk unknown
- 2001-12-20 CN CNA018217508A patent/CN1484642A/zh active Pending
-
2002
- 2002-01-04 AR ARP020100030A patent/AR035679A1/es not_active Application Discontinuation
- 2002-01-04 TW TW091100071A patent/TW591023B/zh not_active IP Right Cessation
- 2002-01-04 PE PE2002000003A patent/PE20020792A1/es not_active Application Discontinuation
-
2003
- 2003-06-02 ZA ZA200304311A patent/ZA200304311B/en unknown
- 2003-06-27 NO NO20032973A patent/NO20032973D0/no not_active Application Discontinuation
- 2003-07-03 EC EC2003004682A patent/ECSP034682A/es unknown
- 2003-07-03 HR HR20030544A patent/HRP20030544A2/hr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
SK8242003A3 (en) | 2004-01-08 |
IL156138A0 (en) | 2003-12-23 |
NO20032973L (no) | 2003-06-27 |
AR035679A1 (es) | 2004-06-23 |
BR0116672A (pt) | 2003-09-23 |
EA200300770A1 (ru) | 2003-10-30 |
HUP0302528A2 (hu) | 2003-11-28 |
CA2431545A1 (en) | 2002-07-11 |
DZ3460A1 (fr) | 2002-07-11 |
PL361934A1 (en) | 2004-10-18 |
MXPA03005981A (es) | 2003-09-10 |
ZA200304311B (en) | 2004-09-02 |
NO20032973D0 (no) | 2003-06-27 |
CZ20031856A3 (cs) | 2003-09-17 |
CN1484642A (zh) | 2004-03-24 |
WO2002053561A1 (en) | 2002-07-11 |
JP2004520335A (ja) | 2004-07-08 |
NZ525821A (en) | 2004-07-30 |
KR20030066797A (ko) | 2003-08-09 |
TW591023B (en) | 2004-06-11 |
EP1351955A1 (en) | 2003-10-15 |
HRP20030544A2 (en) | 2004-08-31 |
PE20020792A1 (es) | 2002-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5271657A1 (es) | Derivados de azaindol | |
EP1602370A3 (en) | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases | |
UY27273A1 (es) | Solución oral de arilpiprazol | |
CY1107146T1 (el) | Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad) | |
CO5280060A1 (es) | Aminoacidos biciclicos como agentes farmaceuticos | |
AR051778A2 (es) | Derivados del acido dimetilaminocrotonico y procesos para supreparacion | |
CO5720995A2 (es) | Compuesto novedoso | |
DE69507614D1 (de) | 3-amino-2-oxo-piperidinessigsäurederivate, die eine argininnachahmende verbindung, mit enzyminhibitorischen wirkung enthalten | |
AR025307A1 (es) | Compuesto de liberacion sostenida de un peptido, microparticulas, composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento | |
CY1120408T1 (el) | Βελτιωμενες φαρμακοτεχνικες μορφες | |
UY27548A1 (es) | Sales de ácido succínico de 5,7,14-triazatetraciclo (10.3.1.02.11.04,9) exadeca-2 (11),3,5,7,9-pentaeno y composiciones farmacéuticas | |
CO5280222A1 (es) | Composicion farmaceutica que comprende pemetrexed | |
ATE322487T1 (de) | Hydroxamsäure-derivate | |
MY133507A (en) | New peroxy-carboxylic acid and aqueous compositions thereof | |
ES2190422T3 (es) | Antagonistas selectivos de receptores de adenosina a2b. | |
AR021232A1 (es) | Procedimiento de preparacion de metionina. | |
DE60115954D1 (de) | Verfahren zur herstellung von gabapentin | |
DE69327890T2 (de) | Verfahren zur Herstellung von 2-(un)substituierten 4-Alkylimidazolen | |
ES2422081T3 (es) | Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales | |
BR0212772A (pt) | Processo para a preparação de repaglinida | |
DE60129442D1 (de) | Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten | |
ECSP034682A (es) | Antagonistas de receptores de aminoacidos excitatorios | |
WO2002026732A1 (fr) | Derive de benzodiazepine | |
BR0110549A (pt) | Processo para a preparação de sais de metais alcalino-terrosos do ácido d-pantotênico | |
DK1180094T3 (da) | Kondenserede polycykliske aminosyrer som farmaceutiske midler |